That’s a Wrap on the 2018 NCRA Convention & Expo

The annual National Court Reporters Association Convention & Expo has wrapped up, and by all accounts, it was a tremendous success. Held in the heart of New Orleans, participants had the opportunity to view the latest and greatest products, take part in valuable learning sessions, and even play games. With so much to see and do, the 2018 NCRA Convention & Expo did not disappoint!

As always, Stenograph was an active contributor to this year’s convention. With the largest booth of any company, we had our newest product offerings on display for convention goers to test out. Stenograph Product Manager Alex Cotteleer remarked, “The energy was great at the show and everyone was genuinely excited about the new offerings.”

New Products and Offerings on Display

Stenograph is constantly innovating products and technology to enhance stenographer performance, and NCRA was the perfect venue to allow the court reporting community the opportunity to experience our latest game-changing offerings and features, including:

  • New Luminex colors – Platinum, Aqua, and Blue Carbon Fiber
  • CasViewNet’s new chat feature
  • Stenograph Askbot community help forum
  • Luminex Wi-Fi capabilities
  • Universal Bar Tension Toggle

Our enormous booth was quite a sight to see, too. Rolling out new products, demonstrating new features, and raising the energy level of the entire building, the Stenograph booth was all the buzz.

Stenograph Training Seminar

Beyond our dynamic booth exhibit and demonstrations, Stenograph also conducted a training seminar at NCRA 2018. During the session, participants were able to learn more about our company and all the product features available to them.

In New Orleans, they say, “Let the good times roll,” and the convention goers took that message to heart. “It was just an overall smooth and positive show,” says Cotteleer.

With such incredible displays, seminars, and activities, the four-day convention in the Big Easy seemed to fly by. Everyone here at Stenograph is thankful to the NCRA and all the expo participants for making this year’s convention one to remember!

Learn more about the new Stenograph products and offerings today!

Read more at stenograph.com

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More